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Background: The chemotherapeutic agent paclitaxel arrests cell division by binding to the hetero-dimeric protein
tubulin. Subtle differences in tubulin sequences, across eukaryotes and among β-tubulin isotypes, can have
profound impact on paclitaxel-tubulin binding. To capture the experimentally observed paclitaxel-resistance of
human βIII tubulin isotype and yeast β-tubulin, within a common theoretical framework, we have performed
structural principal component analyses of β-tubulin sequences across eukaryotes.
Results: The paclitaxel-resistance of human βIII tubulin isotype and yeast β-tubulin uniquely mapped on to the
lowest two principal components, defining the paclitaxel-binding site residues of β-tubulin. The molecular
mechanisms behind paclitaxel-resistance, mediated through key residues, were identified from structural
consequences of characteristic mutations that confer paclitaxel-resistance. Specifically, Ala277 in βIII isotype was
shown to be crucial for paclitaxel-resistance.
Conclusions: The present analysis captures the origin of two apparently unrelated events, paclitaxel-insensitivity of
yeast tubulin and human βIII tubulin isotype, through two common collective sequence vectors.Background
Microtubules are structures composed of polymerized
tubulin heterodimers and play fundamental roles in vital
cellular processes such as chromosome segregation,
intracellular transport and maintenance of cell shape [1].
The major component of microtubules is the hetero-
dimeric (αβ) protein tubulin. Mammalian tissues express
different α- and β-tubulin isotypes [2] that are known to
play specific biological functions, exhibit tissue-
restricted expression, possess differential binding affin-
ities for antimitotic agents and exhibit different kinetics
and dynamics of microtubule assembly [3-5].
Paclitaxel, a product of plant secondary metabolism,
binds to the β-tubulin subunit and inhibits microtubule
dynamics, thereby blocking cell cycle progression during
mitosis at the metaphase/anaphase transition and acti-
vating cell death [6-8]. It is an important cancer che-
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reproduction in any medium, provided the orlung and breast carcinoma, and shows promising activity
against several other carcinomas [9,10]. Although pacli-
taxel is currently used in chemotherapy, clinical resist-
ance against paclitaxel can become a significant
problem. The human βIII tubulin isotype has been
implicated to play a crucial role in conferring paclitaxel
resistance. Increased expression of the βIII tubulin iso-
type inhibits cell proliferation and confers resistance to
paclitaxel [11-13]. Increased relative abundance of the
βIII isotype is also known to destabilize the microtubule
[14] and augment paclitaxel resistance [13,15-17].
Similar to the βIII isotype of mammalian brain tubulin,
tubulin from the budding yeast, Saccharomyces cerevi-
siae, shows weak binding affinity for paclitaxel [18,19]
despite the fact that yeast tubulin shares 75% amino acid
identity with mammalian brain tubulin. When five
amino acid residues in yeast β-tubulin (A19K, T23V,
G26D, N229H, and Y272F) were changed to the respect-
ive residues found in the mammalian brain tubulin, a
paclitaxel-binding site could be created in yeast tubulin
[20]. Of these, the effect from two (A19K and N229H)
was shown to be negligible from single mutational. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Sequence variation at the paclitaxel-binding site (PBS)
of human tubulin isotypes and β-tubulin sequences across
eukaryotic families (shown as sequence logo plots). Sequence
numbering is consistent with that used in the pdb file 1JFF.
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residues, yet there was a dramatic change in the pacli-
taxel binding affinity. This is analogous to the difference
between βIII tubulin and other β-tubulin isotypes (they
differ at only a few sequence positions) where a dramatic
change in paclitaxel affinity is also observed.
Although the final effect of replacing βIII tubulin by
other isotypes, and, mutating yeast tubulin at three spe-
cific positions — regeneration of paclitaxel-binding affin-
ity — is the same, the underlying mechanisms may be
different. Here we focus on deciphering such mechan-
isms, specifically identifying residues and their interac-
tions, responsible for paclitaxel resistance of yeast
tubulin and the βIII tubulin. To identify the role of the
key residues, we analyzed β-tubulin sequences across a
large number of eukaryotic families (animals, fungi, pro-
tists and plants) and performed principal component
analysis (PCA) in the sequence-space defining the
paclitaxel-binding site, obtained from the structure of
paclitaxel-bound αβ-tubulin [22,23]. Projection of bind-
ing site residues on a plane defined by the two principal
component (PC) axes identified two orthogonal ways by
which residues varied across eukaryotes. While the pacli-
taxel resistance of yeast tubulin included contribution
from both the axes, the paclitaxel resistance of the βIII
isotype correlated with contribution from only one of
the two axes. Analysis of structural consequences of
modifying key residues allowed us to identify mechan-
isms of paclitaxel resistance of yeast and the βIII isotype.
Principal component analysis also allowed us to predict
the paclitaxel sensitivity of eukaryotic tubulin for which
experimental data are unavailable.
Results
Multiple sequence alignment of primary paclitaxel-
binding residues
Instead of analyzing the entire tubulin sequence, we ana-
lyzed a sequence subset that is most likely to control
paclitaxel binding. A total of 22 tubulin residues, occur-
ring within 5 Å from paclitaxel in the paclitaxel-bound
tubulin structure (pdb code: 1JFF) [23], were identified
and defined as the paclitaxel binding site (PBS) residues.
From a multiple sequence alignment using the program
ClustalW [24], amino acids corresponding to the 22 PBS
residues were identified in 125 eukaryotic β-tubulin
sequences, as shown in Figure 1 (through out this work
we have used sequence numbering used in the PDB
entry 1JFF; this sequence numbering is slightly different
from the original sequence numbering to accommodate
sequence alignment of α and β–chains). To schematic-
ally depict sequence variations at these residue positions
across the eukaryotic families, sequence logo [25] plots
were constructed for each eukaryotic family, as depicted
in Figure 1. Among the 22 residues, eight residues (27,217, 230, 237, 274, 275, 320, and 360) were strictly con-
served across eukaryotes, while the other 14 showed
mild to strong variation. Among the 14 variable posi-
tions, two positions (23 and 26) correlated with muta-
tional data that resulted in the non-binding of paclitaxel
to yeast tubulin or microtubules [20]. The human β-
tubulin isotypes were also multiple sequence aligned and
the corresponding PBS residues were identified, as
shown in Figure 1. Isotype III has one change (Ser277-
Ala) while isotype VI is characterized by a number of se-
quence variations (Val23Met, Ala233Leu, Ser277Ala and
Arg278Gln).
Principal component analysis in the primary paclitaxel-
binding sequence space
The sequence variations in the PBS (Figure 1) can be
further resolved by principal component analysis. In
summary, PCA seeks vectors that reflect maximum
change in residue variations, in a collective manner.
Two such vectors, PC1 and PC2, associated with the
highest mean square variations, were identified by PCA.
The eukaryotic PBS sequences were then projected onto
a plane defined by PC1 and PC2 (Figure 2a). Before ana-
lyzing Figure 2a, let us recapitulate what is known about
experimental affinities of paclitaxel towards tubulin from
different eukaryotic families (each eukaryotic family is
marked by a different color in Figure 2a). Paclitaxel is
known to interact with animal tubulin/microtubule [26].
Figure 2 Principal component analysis of β-tubulin PBS
residues. a) Projection of β-tubulin PBS on to a plane defined by
the first and second principal component vectors. b) Sequence
variations in each group (A, B, C and D) of panel (a) depicted as
sequence logo plots.
Table 1 Animal β-tubulin sequences used in this work
GI/NCBI Ref. Organism PBS residues Group
(Figure 2)
NM_178014.2 Human (isotype I) EVDDHASFTSRRGL C
NM_001069.2 Human (isotype IIa) EVDDHASFTSRRGL C
NM_178012.4 Human (isotype IIb) EVDDHASFTSRRGL C
NM_006088.5 Human (isotype IVb) EVDDHASFTSRRGL C
NM_006086.3 Human (isotype III) EVDDHASFTARRGL D
NM_006087.2 Human (isotype IVa) EVDDHASFTSRRGL C
NM_032525.1 Human (isotype V) EVDDHASFTSRRGL C
NM_030773.3 Human (isotype VI) EMEDHLSFTAQRGL B
66734014 Ancylostoma duodenale EVDDHVSFSAKRGL D
159161 Haemonchus contortus EVDDHVSFSAKRGL D
62836546 Strongyloides stercoralis EVEDHMSFAARKGL D
3046907 Onchocerca volvulus EVDDHVSFSARRGL D
3046903 Dirofilaria immitis EVDDHVSFSARRGL D
156096 Brugia pahangi EVDDHVSFSARRGL D
19773428 Bombyx mori EIDDHLSFTSRRGL C
16974673 Saimiri sciureus EVDDHASFSSRRGL C
159727 Enteroctopus dofleini EVEDHASFTSRTGL C
289741319 Glossina morsitans EVDDHASFTSRKGL C
135490 Sus scrofa EVDDHASFTSRRGL C
50844501 Bos Taurus EVDDHASFTSRRGL C
10242164 Notothenia coriiceps EVDDHASFTSRRGL C
24645350 Drosophila melanogaster EVDDHASFTSRRGL C
1335661 Patella vulgata EVDDHASFTSRRGL C
56603670 Crassostrea gigas EVDDHASFTSRRGL C
51860821 Loligo pealei EVDDHASFTSRRGL C
74136187 Macaca mulatta EVDDHASFTSRRGL C
90960962 Pan troglodytes EVDDHASFTSRRGL C
49481 Cricetulus griseus EVDDNASFTSRRGL C
6892 Caenorhabditis elegans EVDDHASFTSRRGL C
10242186 Chionodraco rastrospinosus EVDDHASFTSRRGL C
4558495 Trichuris trichiura EVDDHASFTSRRGL C
16974663 Papio hamadryas EVDDHASFTSRRGL C
1769528 Heliothis virescens EVDDHASFTSRRGL C
30088884 Aplysia californica EVDDHASFTSRRGL C
17402390 Fasciola hepatica EVDDHASFTSRRGL C
135489 Paracentrotus lividus EVDDHASFTSRRGL C
7838279 Meriones unguiculatus EVDDHASFTSRRGL C
7838199 Echinococcus multilocularis EVDDHASFTSRRGL C
Sequence numbers: 22-23, 26, 226, 229, 233, 236, 272, 276-278, 369-371.
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[27], maize and tobacco [28,29] are some examples.
Paclitaxel is known to block the growth of Leishmania
donovani, a protist, at low concentrations (<1 μM) [30].
However paclitaxel is insensitive to tubulin from fungi,
the prime example being budding yeast S. cerevisiae
[19]. However, the apparent eukaryotic family-specific
paclitaxel-binding trait of β-tubulin is not reflected in
Figure 2a. An examination of Figure 2a shows that there
is no clear eukaryotic-family specific clustering, except
that the PC1 projections of most fungal β-tubulins are
positive.
To understand Figure 2a better, we divided the pro-
jected PBS site residues into four groups (clusters) — A,
B, C and D (see Tables 1, 2, 3, 4). Sequence alignments
of members belonging to each group yielded foursequence logo plots, as shown in Figure 2b. These se-
quence logo plots represent the overall features of the
respective groups. Dominant sequence changes, in going
from one group to the other, either vertically or
Table 2 Fungi β-tubulin sequences used in this work
GI/NCBI Ref. Organism PBS residues Group
(Figure 2)
4455142 Lentinus sajor-caju EVDDHISFTARRGC D
173523 Schizophyllum commune EVDDHFSFTARRGL D
74699315 Ustilago maydis EVDDHLSFTARRGL D
11229034 Melampsora lini EVDDHISFTARRGL D
55982602 Cochliobolus heterostrophus EVDDHSSFTSRRGL C
173523 Schizosaccharomyces pombe STDDHAAFAAIKDL B
3435 Saccharomyces cerevisiae ETGDNSSYTAIQGL B
170938 Candida albicans ETGENSSYTSMKDL B
77023508 Verticillium tricorpus QNGDHASFTSRRGL A
299296 Phaeosphaeria nodorum QTGDHASFTSRRGL A
58119500 Phaeosphaeria avenaria QTGDHASFTSRRGL A
170600 Venturia inaequalis QTGDHASFTSRRGL A
61678005 Cercospora beticola QTGDHASFTSRRGL A
30961893 Monilinia fructicola QTGDHASFTSRRGL A
166496 Aspergillus flavus QTGDHASFTSRRGL A
168105 Emericella nidulans QTGDHASFTSRRGL A
639766 Ajellomyces capsulatus QTGDHASFTSRRGL A
2852439 Mycosphaerella pini QTGDHASFTSRRGL A
1002511 Botryotinia fuckeliana QTGDHASFTSRRGL A
602578 Erysiphe pisi QTGDHASFTSRRGL A
1060942 Penicillium digitatum QTGDHASFTSRRGL A
6652864 Pestalotiopsis microspora QTGDHASFTSRRGL A
1263904 Rhynchosporium secalis QTGDHASFTSRRGL A
2718 Epichloe typhina QTGDYASFTSRRGL A
849160 Gibberella fujikuroi QTGDYASFTSRRGL A
2293 Neotyphodium coenophialum QTGDYASFTSRRDL A
32130590 Gibberella zeae QTGDYASFTSRRGL A
167300 Glomerella graminicola QTGHHRSFTS-KGL A
169400 Pneumocystis carinii STGDHASFTSKRGL A
Sequence numbers: 22-23, 26, 226, 229, 233, 236, 272, 276-278, 369-371.
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A277S (vertical move). Groups A and B exclusively con-
tain members of the fungi family. Group C contains all
members of the plant family and majority of the animal
and the protist family. However, it also contains a fungal
pathogen of maize, Cochliobolus heterostrophus. Group
D contains members from all families except plants. Pro-
jection of human β-tubulin isotypes on the PC1-PC2
plane showed that all isotypes appear in group C except
β-III (group D) and β-VI (group B).
Paclitaxel indifference of yeast and βIII-tubulin isotype
reflected on the first two principal components
The identities of PBS residues were explored along PC1
or PC2 axes. Amino acid variations along PC1 and PC2axes are shown in Figure 3. Among the five residue
mutations that altered yeast tubulin affinity towards
paclitaxel (A19K, T23V, G26D, N229H, and Y272F), two
(T23V and G26D) are captured by the PC1 axis. Two
other residue variations (N229H, and Y272F) get
reflected along the PC2 axis (the fifth residue, A19K, is
not part of the PBS). The only residue that makes the
βIII-isotype unique is Ala277 (in place of Ser). This vari-
ation is reflected along the PC2 axis. It is noteworthy
that the PCA was performed without the inclusion of
the β-tubulin isotypes. Yet, sequence variations at the
PBS in the isotype sequences (position 277) are reflected
in one of the two PC axes. This shows that the two PC
axes are quite robust. The Ala/Ser variation at position
277 is naturally present, not only in isotypes βIII and
Table 3 Plant β-tubulin sequences used in this work
GI/NCBI Ref. Organism PBS residues Group
(Figure 2)
4455142 Lentinus sajor-caju EVDDHISFTARRGC C
1488052 Daucus carota EVDDHGSFTSRRGL C
460991 Oryza sativa EVDDHASFTSRRGL C
4415996 Eleusine indica EVDDHASFTSRRGL C
224106013 Populus trichocarpa EVDDHASFTSRRGL C
1403143 Cicer arietinum EVDDHASFTSRKNL C
244539475 Lotus japonicus EVDDHASFTSRKGL C
153799899 Eucalyptus grandis EVDDHASFTSRKGL C
255564502 Ricinus communis EVDDHASFTSRKGL C
312989 Glycine max EVDDHASFTSRKGL C
223018283 Citrus maxima EVDDHASFTSRKGL C
295851 Zea mays EVADHASFTSRHGL C
609270 Solanu tuberosum EVDDHASFTSRTGL C
77963735 Solanum lycopersicum EVDDHASFTSRTGL C
40036995 Nicotiana attenuata EVDDHASFTSRTGL C
1743277 Hordeum vulgare EVDDHASFTSRTGL C
14331109 Medicago sativa EVDDHTSFTSRTGL C
145388977 Capsicum annuum EVDDHASFTSRTGL C
37038246 Physcomitrella patens EVEDHASFTSRTGL C
402636 Lupinus albus EVADHASFTSRTGL C
20758 Pisum sativum EVADHASFTSRTGL C
20148289 Arabidopsis thaliana EVADHASFTSRTGL C
51988178 Setaria viridis EVADHASFTSRTGL C
205326619 Prunus salicina EVADHASFTSRTGL C
5668669 Zinnia elegans EVTDHASFTSRTGL C
296498 Anemia phyllitidis EVTDHASFTSRVGL C
4098333 Triticum aestivum EVGDHASFTSRVGL C
19569609 Gossypium hirsutum EVADHASFTSRIGL C
Sequence numbers: 22-23, 26, 226, 229, 233, 236, 272, 276-278, 369-371.
Table 4 Protist β-tubulin sequences used in this work
GI/NCBI Ref.Organism PBS residues Group
(Figure 2)
155874 Babesia bovis EVDDHASFTSRKGL C
29420520 Babesia microti EVDDHASFTSRKGL C
295762 Plasmodium falciparum EVDDHASFTSRKGL C
4079637 Tetrahymena pyriformis EVDDHASFTSRKGL C
161737 Tetrahymena thermophila EVDDHASFTSRKGL C
6007456 Stylonychia mytilus EVDDHASFTSRKGL C
9309 Euplotes octocarinatus EVDDHASFTSRKGL C
2155306 Chlamydomonas incerta EVDDHASFTSRKGL C
167456 Chlamydomonas reinhardtii EVDDHASFTSRKGL C
166302 Achlya klebsiana EVDDHASFTSRKGL C
68128910 Leishmania major EVDDHASFTSRKGL C
6652866 Pythium ultimum EVDDHASFTSRKGL C
639490 Eimeria tenella EVDDHASFTSRKGL C
161939 Toxoplasma gondii EVDDHASFTSRKGL C
23481527 Plasmodium yoelii yoelii EVDDHASFTSRKGL C
290685 Moneuplotes crassus EVDDHASFTSRKGL C
38520885 Paramecium tetraurelia EVDDHASFTSRKGL C
295443942 Palpitomonas bilix EVDDHASFTSRKGL C
238617571 Leucocryptos marina EVDDHASFTSRKGL C
302849658 Volvox carteri EVDDHASFTSRKGL C
135500 Trypanosoma brucei rhodesiensEVDDHASFTSRKGL C
206598211 Bodo saltans EVDDHASFTSRKGL C
159416 Leishmania mexicana EVDDHASFTSRKGL C
135494 Polytomella agilis EVDDHASFTSRKGL C
829213 Naegleria gruberi EVDDHISFTSRRGL C
8926601 Thalassiosira weissflogii EVDDHACYTSRKGL C
2951981 Phytophthora cinnamomi EVDDHASFTSRQGL C
29150706 Porphyra yezoensis EVEDKGSYSADTGE D
29539330 Cyanidioschyzon merolae EVEDKGSLTATKGL D
1067176 Porphyra purpurea EVEDKGSYSADTGE D
Sequence numbers: 22-23, 26, 226, 229, 233, 236, 272, 276-278, 369-371.
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sections we provide structural arguments as to why
members of groups A, B and D might be paclitaxel-
insensitive.
Structural consequences of Val23Thr and Asp26Gly
mutation
Compared to group C that contains paclitaxel-sensitive
β-tubulin sequences, Val23Thr and Asp26Gly mutations
characterize groups B and A (positive PC1 values). If
these mutations are indeed responsible for paclitaxel-
insensitivity, what is the structural mechanism behind
paclitaxel-resistance? In Figure 4a paclitaxel is shown
with Asp26 and Val23 as found in the structure 1JFF.
The structural consequences of Asp26Gly and Val23Thr
mutations are shown in Figure 4b. The large side chainof Asp molecule strongly interacts with 3′-phenyl group
(Figure 4a) of paclitaxel. Asp26Gly mutation will clearly
have a major effect since the Asp side-chain makes sev-
eral contacts with paclitaxel that will be lost. However,
the effect of Val23Thr mutation on paclitaxel-sensitivity
of β-tubulin is not apparent from Figure 4a. To fully
understand the effect of Val23Thr mutation, one needs
to examine alternate rotameric states of Thr23. In the
new rotameric state (Figure 4c) the side-chain of Thr23
can form a H-bond with the backbone carbonyl atoms
of Lys19 and Phe20. Although this new interaction is a
little distant from paclitaxel, it can have subtle but im-
portant effect on paclitaxel-binding. As shown in
Figure 4d, Lys19, Phe20, Val23, and Asp26 β-tubulin is
Figure 3 Variations of amino acid composition (from the
average composition of the entire data set) at the PBS, as
principal component 1 (PC1) and principal component 2 (PC2)
vectors deviate from their respective mean (zero) values.
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well as in paclitaxel-free (pdb code: 1SA0) structure.
However, paclitaxel-binding distorts the helix. Upon
Val23Thr mutation, the side-chain hydroxy group of ThrFigure 4 Paclitaxel-bound (pdb ID:1JFF) and paclitaxel-free (pdb ID: 1
paclitaxel-bound β-tubulin (pdb ID:1JFF). b) Same as panel (a) with two in
the original pdb file (1JFF) was maintained during the mutation. c) Identica
to a new rotameric state. In the new rotameric state, the sidechain of Thr2
Phe20 and Lys19. d) An α-helix in β-tubulin (containing residues 19, 20 and
(paclitaxel-bound).can potentially form a H-bond with the backbone oxy-
gen atom of Phe 20 and Lys 19 (Figure 4c). Therefore,
the observed helix distortion is harder to achieve when
Val gets mutated to Thr at position 23. This extra H-
bond formed by Thr 23 will be detrimental to paclitaxel-
binding. In other words, Val23Thr mutation can affect
paclitaxel sensitivity in an indirect manner.Structural consequences of Ser277Ala mutation
Serine is present at position 277 in βIII and βVI isotypes
(the βVI isotype also has amino acid changes at other
positions) while all other isotypes contain Ala at this
position (Figure 1). Here we explore mechanisms by
which Ser277Ala mutation can give rise to paclitaxel re-
sistance. This amino acid change was reflected in the
PC2 axis. As shown in Figure 5, Ser277 is present in a
flexible loop around the bound paclitaxel in 1JFF and is
proximal to another loop containing Lys218. That the
loops are flexible and become more ordered upon bind-
ing paclitaxel is clear from the fact that in the paclitaxel-SA0) β-tubulin. a) Disposition of Val23, Asp26 and paclitaxel in
silico mutations: Val23Thr and Asp26Gly. The rotameric state of Val23 in
l to panel (b) except that the side-chain of Thr23 has been changed
3 can form a H-bond with the backbone carbonyl oxygen atoms of
23) as found in two crystal structures: 1SA0 (paclitaxel-free) and 1JFF
Figure 5 Loop-loop interactions in paclitaxel-bound animal β-
tubulin (pdb ID: 1JFF). a) The side-chain of Ser277 is shown in two
rotameric states— the first rotamer (as found in 1JFF) lacks Ser277-
Lys218 interaction while the second rotamer (generated in silico)
shows Ser277-Lys218 H-bond (blue line) interaction. The interaction
between Ser280 and Lys218 is present in the crystal structure. b)
Disposition of loops of panel (a) with two in silico mutations (S277A
and K278I; 277A and 278I are present in yeast β-tubulin) exhibiting a
three-center hydrophobic interaction (L219-L217-I278).
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the loops is disordered in β-tubulin. Upon paclitaxel
binding (pdb ID: 1JFF) this loop becomes ordered. Inter-
actions between the two loops present in 1JFF are shown
in Figure 5a. In the paclitaxel-bound state, the side chain
hydroxyl group of Ser280 forms a H-bond with the side
chain nitrogen of Lys218 (note that residue 280 is disor-
dered in 1SA0 and so no such interaction is present).
This indicates that interaction of the two loops is im-
portant for paclitaxel binding. Ser277 does not partici-
pate in loop-loop interaction in the paclitaxel-bound
structure. Side-chain rotamers are often missed in pro-
tein structures, especially in structures like 1JFF, which
was determined by electron diffraction and has a rather
low resolution (3.5 Å). So we altered (in silico) the rota-
meric state of Ser277 to examine if that would introduce
any loop-loop interaction. Indeed, as shown in
Figure 5a, one rotameric state of Ser277 showed side-
chain H-bonding to the backbone amide of Lys 218. Thisindicates that upon Ser277Ala mutation, the possibility
of formation of an additional H-bond formation would
be lost. This loss of additional H-bond energy may be in-
directly responsible for resistance of isotype βIII by dir-
ectly affecting loop-loop interaction.
Why mutated yeast β-tubulin is paclitaxel-sensitive even
with Ala at position 277
S. cerevisiae β-tubulin, a member of group B in
Figure 2a, is paclitaxel-insensitive. According to the
major amino acid changes among the quadrants, this is
due to the presence of: i) Ala instead of Ser at position
277, and, ii) Thr and Gly (instead of Val and Asp) at
positions 23 and 26 respectively. Paclitaxel-sensitivity in
S. cerevisiae was achieved with three single mutations:
Thr23Val, Gly26Asp and Tyr272Phe. However, Ala277
was unaltered in that experiment. According to the
arguments presented above, β-tubulin of the triple mu-
tant would still be paclitaxel insensitive since Ala 277
(instead of Ser 277) will destabilize the loop-loop inter-
action. The reason why this is not the case becomes
clear if one looks at the sequence of yeast β-tubulin
(Table 2). The presence of Ile in place of Arg/Lys (con-
served in all other members except the three quadrant B
sequences) is conspicuous at position 278, a position
that follows Ala277. If one examines the tubulin struc-
ture, Ile278 is in proximity to Leu217 and Leu 219
(Figure 5b) allowing the formation of a three-center
hydrophobic staple, stabilizing the loop-loop interaction.
In other words, although yeast β-tubulin lacks the po-
tential loop-loop interaction mediated by Ser277-Lys218
H-bond, its absence is compensated by an alternate po-
tential loop-loop interaction mediated by a three-
centered hydrophobic staple Ile-Leu-Leu (278-217- 219).
Consequences of mutations in yeast β-tubulin at
positions 19, 229 and 272
Of the five mutations that transformed yeast β-tubulin
from paclitaxel non-binder to paclitaxel-binder, we have
discussed structural consequences of only two: T23V
and G26D. Here we look at the other three mutations.
Interactions of residues His229 and Phe272 with pacli-
taxel in 1JFF are shown in Figure 6a. While His partici-
pates in stacking interactions, Phe participates in an
edge-edge interaction with paclitaxel. The His229Asn
mutation will clearly disrupt the stacking interaction and
affect paclitaxel-binding affinity. However, it seems that
Phe272Tyr mutation may not play an important role in
disrupting paclitaxel-β-tubulin interaction. However,
only experiments with single mutants can clearly address
the importance of the F272Y mutation. We did not con-
sider residue 19 in our work since it was not part of the
PBS. In fact, as shown in Figure 6b, residue 19 is quite
distant from paclitaxol in 1JFF. Nonetheless, its
Figure 6 Disposition of a) paclitaxel, Phe272 and His229, and b) paclitaxel, Lys19 and Glu22 in paclitaxel-bound β-tubulin (pdb ID:
1JFF). Although Lys19 is far from paclitaxel, its role in intra-helix interaction is emphasized by its proximity to Glu22.
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interaction between Lys19 and Glu22, stabilizing a helix
proximal to paclitaxel. To summarize, K19A mutation
can directly affect the stabilization of a helix proximal to
paclitaxol and affect binding. The H229N mutation can
disrupt an important stacking interaction and affect
binding. The F272Y mutations may not play an import-
ant role in modulating paclitaxel binding.Discussion
Paclitaxel is an important chemotherapeutic drug that
binds β-tubulin and modulates microtubule formation
and dynamics. The paclitaxel-binding site on β-tubulin
has been identified from the structure of paclitaxel-
bound β-tubulin. In addition, a large number of β-
tubulin sequences across all four eukaryotic families are
known. Using the paclitaxel-bound β-tubulin structure
and the β-tubulin sequence database we have attempted
to rationalize two apparently unrelated experimental
data, relevant to paclitaxel-β-tubulin binding: 1) induc-
tion of paclitaxel resistance upon over expression of
human tubulin βIII-isotype [11-17], 2) yeast β-tubulin,
which otherwise does not bind paclitaxel, becomes
paclitaxel-sensitive upon mutation at five positions
[20,21].
Using the paclitaxel-bound β-tubulin structure and
multiple sequence alignment, paclitaxel-binding site resi-
dues in β-tubulin across eukaryotic families were identi-
fied. Subsequently PCA was performed in the sequence
sub-space comprising the binding site. By projecting the
binding site residues onto the first two PC vectors we
checked if the sequences from fungal tubulin formed a
cluster, since available experimental data suggests that
only members of the fungi family are paclitaxel-
insensitive. However, no clear fungi family-specific clus-
tering was obtained. In a previous study a similar ap-
proach yielded a very clear family-specific clustering of
tubulin sequences, correlating with experimental data,where the focus was on the binding site of another anti-
mitotic drug, colchicine [31].
Of the three mutations in yeast β-tubulin that ren-
dered it paclitaxel-sensitive, two (T23V and G26D) were
captured by the PC1 axis and one (Y270F) was captured
by the PC2 axis. The distribution of the three mutations
in two axes allowed us to define four clusters in the
PC1-PC2 plane. Most animals and protists, including all
plants, were found in one cluster (C). Representative
members of these families are known to be paclitaxel-
sensitive. However quadrant C also contained one mem-
ber of the fungi family, C. heterostrophus. Close inspec-
tion of the sequences of members of cluster C (Table 1)
shows that C. heterostrophus is unique among members
of the C cluster. In C. heterostrophus the sequence pos-
ition 233 is occupied by Ser, while for all other members,
this position is occupied by Ala/Leu/Met/Val/Gly/Ile.
Therefore the sole member of the fungi family in this
cluster is unique and might actually be paclitaxel-
insensitive. The rest of the members of the fungi family
were distributed in the other three clusters, uniquely
characterized by the presence of mutations responsible
for paclitaxel-insensitivity. Structural consequences of
mutations leading to paclitaxel-insensitivity in yeast
tubulin and members present in clusters A, B and D of
the PC1-PC2 projection were examined and it was
shown that while some mutations will have a direct con-
sequence, for others the consequences of mutations on
paclitaxel-binding may be indirect.
The only position in the PBS where a residue change
correlated with paclitaxel-insensitivity change in human
β-tubulin isotypes (Ser277Ala mutation) was captured
by PC2 axis even though tubulin isotype sequences were
excluded in the PCA. This is a striking result and shows
that the two PC axes not only capture inter-species se-
quence variations they also naturally capture intra-
species sequence changes at critical amino acid positions
in the PBS. The structural role of Ser277 has recently
been studied by docking and molecular dynamics studies
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antimitotic agents, where it was shown that Ser277 plays
a crucial role in intra-loop interaction critical for pacli-
taxel binding [32]. We showed that Ser277 also plays an
important role in inter-loop interaction that can affect
paclitaxel binding. Despite being a critical residue,
Ser277Ala mutation can still allow paclitaxel binding,
provided there are alternate mechanisms of loop-loop
interaction, as evident from mutated yeast tubulin where
a Ser277Ala mutation is compensated by Arg278Ile mu-
tation, giving rise to a three-center hydrophobic staple.
In addition, human βVI tubulin isotype, which also con-
tains Ala277, may actually be paclitaxel sensitive due to
other compensatory mutations (Arg278Gln, Ala233Leu).
Conclusions
In summary, we have rationalized two apparently unre-
lated experimental data — differential paclitaxel binding
among mammalian β-tubulin isotypes and that between
wild type and yeast β-tubulin mutated at six positions —
in terms of two collective sequence vectors, PC1 and
PC2, spanning the PBS. PCA has previously been suc-
cessful in predicting protein functional residues [33] and
rationalizing the differential colchicine-binding of
animal-tubulins [31]. The present analysis extends the
applicability of PCA to paclitaxel-tubulin interaction
with valuable insights and specific predictions.
Methods
A total of 125 β-tubulin (animal: 38, fungi: 29; protists:
30; plant: 28) sequences were used in this work. The se-
quence accession numbers and the names of the corre-
sponding organisms are given in Tables 1, 2, 3, 4. The
structures for paclitaxel-bound (PDB ID: 1JFF) [23] and
paclitaxel-free (PDB ID: 1SA0) [34] tubulin were down-
loaded from the protein data bank [35]. Structural ana-
lysis was performed using the program Chimera [36].
The primary paclitaxel binding site (PBS) was defined by
residues in 1JFF that were within 5 Å of paclitaxel (dis-
tance between atoms of paclitaxel and any heavy atom
of tubulin). Amino acid residues within 5 Å from the
bound paclitaxel molecule are given in Figure 1. Mul-
tiple sequence alignments were performed using the
program ClustalW [24] to identify PBS residues in all β-
tubulin sequences corresponding to that defined in 1JFF.
Subsequently, Principal Component Analysis (PCA)
was performed in the multi-dimensional sequence-space
of PBS, as previously described [31]. Each sequence pos-
ition was represented by a binary-vector (of length 21),
where the first twenty elements represent the occurrence
of a particular amino acid (1 for presence and 0 for ab-
sence), and the last element represents the presence of a
gap. For example, Ala is represented by {1, 0, 0, 0, 0, 0,
0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0} and a gap isrepresented by {0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,
0, 0, 0, 1}. The PBS residues (22 residue positions, of
which 14 positions showed amino acid variations) from
each β-tubulin sequence (a total of M sequences) was
represented by a binary-vector {aik} where the i-th index
represents a particular β-tubulin sequence (i= 1, M) and
the k-th index runs from 1 to N (N= 14 × 21). The N ×




aik  akð Þ ail  alð Þ= M  1ð Þ ð1Þ










In Eq. 1, the denominator (M - 1), instead of M, is
used to yield an unbiased estimator of the (co)variance.
The variance-covariance matrix was diagonalized yield-
ing N principal component vectors (eigen vectors ! V k ;
k= 1, N) and N eigen values (mean square variation
associated with each eigen vector) λk (k= 1, N). The pro-
jection of the i-th β-tubulin PBS sequence on the k-th
PC vector ! V k was calculated from the dot product of
i-th sequence vector { ai1; ai2 . . . aiN } and the k-th PC
vector {vk1; vk2 . . . vkN }.
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